No abstract

This article explores the critical factors of consumption in Mexico, Ecuador, and Colombia, due to confinement and social distancing. Besides, which are the factors that influence the purchase decision. In the proposed model, we tested from quantitative research with a sample of 2,065 online consumers. We analyzed the following statistics: CFA, structural equations, invariance of measurement instruments, and multi-group analysis with the Smart Pls 3 and EQS 6.3 software. The study reveals that time, space, and place in the consumption process is more visible in the purchasing behavior with social distancing, healthy distance, and the commercial restriction caused by the health contingency. In addition to being a health and humanitarian crisis, the pandemic has severe economic consequences worldwide as 1) the increase in unemployment rates, 2) collapsed health systems, 3) education models overwhelmed by technology, 4) supply chains interrupted by the closure of borders, 5) international and domestic tourism suspended due to a lack of sanitary protocols,6) social coexistence curtailed by significantly increased infections and 7) a decreasing demand by consumers for the closure of companies. Despite being Latin American countries, cultural differences were not the priority of consumption in the crisis period due to Covid-19. They significantly change purchasing behaviors, and all have adapted to online and home delivery purchases by the social factor, local consumption, and consumers' attitude. The article presents several considerations on the main factors of consumption in Covid-19 in collectivist countries (North American and South America) such as Mexico, Colombia, and Ecuador and finds no substantial differences with consumers. There are practical implications for companies to adopt online channels and to create sales strategies in the face of the endemic pandemic.

SummaryMantle cell lymphoma (MCL) after relapse is associated with poor prognosis. No standard of care exists and available evidence for treatments is limited, particularly in patients who fail Bruton tyrosine kinase inhibitor (BTKi) therapy. This multicentre retrospective chart review study, SCHOLAR‐2, addresses this knowledge gap and reports on data collected from 240 patients with relapsed/refractory MCL in Europe who were treated with BTKi‐based therapy between July 2012 and July 2018, and had experienced disease progression while on BTKi therapy or discontinued BTKi therapy due to intolerance. The median overall survival (OS) from initiation of first BTKi therapy was 14.6 months (95% confidence interval [CI] 11.6–20.0) in the overall cohort, 5.5 months (95% CI 3.9–8.2) in 91 patients without post‐BTKi therapy, and 23.8 months (95% CI 18.9–30.1) in 149 patients who received post‐BTKi therapy (excluding chimeric antigen receptor T‐cell treatment). In the latter group, patients received a median of one (range, one to seven) line of post‐BTKi therapy, with lenalidomide‐containing regimens and bendamustine plus rituximab being the most frequently administered; the median OS from initiation of first post‐BTKi therapy was 9.7 months (95% CI 6.3–12.7). These results provide a benchmark for survival in patients with R/R MCL receiving salvage therapy after BTKi failure.

The ELARA trial indicates tisagenlecleucel (tisa-cel) is an effective anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory follicular lymphoma (r/r FL). As ELARA is single-arm, this study compared tisa-cel outcomes from ELARA with usual care from a real-world cohort. ELARA enrolled 98 patients as of 29Mar2021 (median follow-up: 15 months from enrollment). Usual care data came from ReCORD-FL, a global retrospective study of r/r FL patients who met similar eligibility criteria to ELARA. With data cutoff of 31Dec2020, 187 patients with ≥2 prior treatment lines were included in ReCORD-FL (median follow-up: 57 months from third-line). Indirect treatment comparison was performed for 97 ELARA and 143 ReCORD-FL patients with no missing data on baseline factors. The line of therapy for which outcomes were assessed was selected/matched between cohorts using propensity score modeling. After baseline factor adjustment via weighting by odds, complete response rate (CRR; 95% confidence interval) was 69.1% (59.8%-78.3%) for tisa-cel vs. 37.3% (26.4%-48.3%) for usual care; overall response rate was 85.6% (78.7%-92.5%) vs. 63.6% (52.5%-74.7%). Kaplan-Meier probability of being progression/event-free at 12 months was 70.5% (61.4%-79.7%) for tisa-cel vs. 51.9% (40.6%-63.3%) for usual care, with hazard ratio (HR)=0.60 (0.34-0.86); 12-month overall survival was 96.6% (92.9%-100%) vs. 71.7% (61.2%-82.2%), with HR=0.2 (0.02-0.38). In conclusion, tisa-cel was associated with 1.9-fold higher CRR and 1.4-fold higher rate of being progression/event-free at 12 months versus usual care, as well as death risk reduction of 80%. Findings provide additional evidence on the benefit of tisa-cel in r/r FL patients after ≥2 treatment lines. This trial is registered at www.clinicaltrials.gov as NCT03568461.

This study (ReCORD-FL) sought to construct a historical control cohort to augment single-arm trials in relapsed/refractory follicular lymphoma (r/r FL). A retrospective study in 10 centers across North America and Europe was conducted. Adults with grade 1-3A FL were required to be r/r after ≥2 therapy lines including an anti-CD20 and an alkylator. After first becoming r/r, patients were required to initiate ≥1 additional therapy line, which defined the study index date. Endpoints were observed from start of each therapy line (including index line) until death, last follow-up, or December 31, 2020. Endpoints were complete response (CR) rate, overall response rate (ORR), time to next treatment or death (TNT-D), event-free survival (EFS), and overall survival (OS). One hundred eighty-seven patients were identified. Most patients' (80.2%) index therapy occurred in third line (3L) (range, 3L-6L). Median follow-up from FL diagnosis was 9 years (range, 1-21 years). CR and ORR to the index therapy were 39.0% and 70.6%, respectively. Median (95% confidence interval) EFS from index was 14.6 (11.0-18.0) months; median OS from index was 10.6 years. Outcomes worsened across successive treatment lines and for patients who were double refractory (r/r to both an anti-CD20 monoclonal antibody and an alkylator) or POD24 (progressed ≤24 months after front-line anti-CD20) at index. Findings demonstrate the unmet need of FL patients with multiply relapsed, double refractory, or POD24 disease. Based on robustness of the historical data collected and comparability with a previous study (SCHOLAR-5), ReCORD-FL presents a valuable source of control data for comparative studies in r/r FL.